{"id":"NCT02326298","sponsor":"UCB Biopharma S.P.R.L.","briefTitle":"An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-16","primaryCompletion":"2016-03-08","completion":"2018-10-24","firstPosted":"2014-12-29","resultsPosted":"2018-08-13","lastUpdate":"2019-11-07"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis","Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870","CZP"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"CZP 200 mg","type":"EXPERIMENTAL"},{"label":"CZP 400 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.","primaryOutcome":{"measure":"Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Placebo Q2W (RS)","deltaMin":6.5,"sd":null},{"arm":"CZP 200 mg Q2W (RS)","deltaMin":66.5,"sd":null},{"arm":"CZP 400 mg Q2W (RS)","deltaMin":75.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":30,"countries":["United States","Canada","Czechia","Germany","Hungary"]},"refs":{"pmids":["29660421","36509889","32652544","32531798"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":188},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Back pain","Headache","Arthralgia"]}}